Ladenburg Thalmann Financial Services’s Adicet Bio ACET Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Buy	+9	New	+$4.56K	﹤0.01%	5159

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ACET Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Adicet Bio (ACET) in Q4 2019: 9 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #5159 among its holdings.

54 funds tracked by Wall St. Rank hold ACET as of Q4 2019.

Ladenburg Thalmann Financial Services held 9 shares of Adicet Bio worth $1K as of Q4 2019.
Adicet Bio was a new Ladenburg Thalmann Financial Services position in Q4 2019.
Adicet Bio made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5159 holding.
54 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.